Selective inhibition of COX-2 activity with celecoxib in senescent fibroblasts significantly constrained the release of PGE2 and SASP component IL-6, and diminished chemotaxis of cancer cells in vitro to levels similar to those of untreated proliferating control (Fig 5C-E). This evidence concerns the gene IL6 and cancer.